<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301440</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A03150-57</org_study_id>
    <nct_id>NCT04301440</nct_id>
  </id_info>
  <brief_title>THE PHYSIOLOGICAL EFFECTS OF ELECTROMAGNETIC EMISSIONS ON THE GENERAL CONDITION OF THE PATIENT</brief_title>
  <acronym>EPHEME</acronym>
  <official_title>THE PHYSIOLOGICAL EFFECTS OF ELECTROMAGNETIC EMISSIONS ON THE GENERAL CONDITION OF THE PATIENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Bizet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Bizet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hospital patients usually experience anxiety caused by physiological, psychological and&#xD;
      environmental stimuli. This emotional state corresponds to the psychophysiological response&#xD;
      to a perceived threat.&#xD;
&#xD;
      The investigator's goal is to use a non-drug approach to these problems which would help&#xD;
      improve the quality of life of patients, prevent the consumption of anti-anxiety drugs /&#xD;
      antidepressants; and thus to reduce the direct cost in terms of treatment, but also to reduce&#xD;
      the indirect costs linked to work stoppages and the consumption of the care offer.&#xD;
&#xD;
      Working hypothesis: Local magnetic muscle stimulation improves people's well-being and&#xD;
      relaxation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective :&#xD;
&#xD;
      Describe the effect of the intervention on the level of anxiety / depression in patients with&#xD;
      anxious and / or depressive characteristics&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Describe the variation in the quality of life of patients before and after the&#xD;
           intervention&#xD;
&#xD;
        -  Describe the variation in drug consumption&#xD;
&#xD;
        -  Describe the use of post intervention hospitalization&#xD;
&#xD;
        -  Describe the variation in the quality of sleep before and after the intervention&#xD;
&#xD;
        -  Describe the timeframe for returning patients to professional activity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2020</start_date>
  <completion_date type="Actual">May 28, 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study concerns adult patients hospitalized for the management of a chronic pathology and / or its complications</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved quality of life in depressed and anxiety patients: Hospital Anxiety and Depression scale</measure>
    <time_frame>Ten days</time_frame>
    <description>Evaluation with Hospital Anxiety and Depression scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decreased consumption of anti-anxiety and anti-depressant drugs</measure>
    <time_frame>Ten days</time_frame>
    <description>Prescription analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improved quality of sleep: Epworth scale</measure>
    <time_frame>Ten days</time_frame>
    <description>Evaluation with Epworth scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Electromagnetic Emissions and Emotional Disorder</condition>
  <condition>Electromagnetic Emissions and Medication Savings</condition>
  <arm_group>
    <arm_group_label>patients with anxious and / or depressive characteristics : treated group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with anxious and / or depressive characteristics, The device with the electromagnetic wave will be connected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with anxious and / or depressive characteristics : placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The device with the electromagnetic wave will not be connected</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The emission of electromagnetic with the probes</intervention_name>
    <description>The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.</description>
    <arm_group_label>patients with anxious and / or depressive characteristics : treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The emission of electromagnetic without the probes</intervention_name>
    <description>The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.</description>
    <arm_group_label>patients with anxious and / or depressive characteristics : placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient hospitalized for the management of a chronic pathology and / or its&#xD;
             complications;&#xD;
&#xD;
          -  Patient with a Hospital Anxiety and Depression scale score (HAD) ≥ 8 for items&#xD;
             assessing anxiety disorders; AND a HAD score ≥ 8 for the items assessing depressive&#xD;
             disorders.&#xD;
&#xD;
          -  Subject affiliated to a social security scheme or beneficiary of such a scheme&#xD;
&#xD;
          -  No participation in another clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor patient&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
          -  HAD score &lt;8 for items evaluating anxiety disorders OR a HAD score &lt;8 for items&#xD;
             evaluating depressive disorders&#xD;
&#xD;
          -  Major subject protected by law, under curatorship or tutorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Benkessou</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Medication savings</keyword>
  <keyword>Electromagnetic emissions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

